Compare BridgeBio Pharma Inc (BBIO) vs L3Harris Technologies Inc (LHX) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.

The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.

LHX trades at $289.72, up 1.06% on the day, with a bearish technical signal but strong fundamental momentum. Recent earnings beats, including Q2 2026 EPS of $3.13 versus $2.80 expected, and a record $42 billion backlog support growth. The company completed a strategic divestiture and secured key defense contracts, enhancing its positioning in missile defense and space systems.

Outlook is positive with analyst consensus price target of $319.33 implying ~10% upside, though technical indicators signal near-term caution. Risks include execution on production ramp-ups and defense budget volatility, but robust cash flow and dividend payments provide shareholder stability.